[go: up one dir, main page]

WO1999022720A3 - Selective cyclooxygenase-2 inhibitors against premature labor - Google Patents

Selective cyclooxygenase-2 inhibitors against premature labor Download PDF

Info

Publication number
WO1999022720A3
WO1999022720A3 PCT/US1998/022246 US9822246W WO9922720A3 WO 1999022720 A3 WO1999022720 A3 WO 1999022720A3 US 9822246 W US9822246 W US 9822246W WO 9922720 A3 WO9922720 A3 WO 9922720A3
Authority
WO
WIPO (PCT)
Prior art keywords
selective cyclooxygenase
premature labor
inhibitors against
against premature
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/022246
Other languages
French (fr)
Other versions
WO1999022720A2 (en
Inventor
Philip Needleman
Jaime Masferrer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Priority to JP2000518654A priority Critical patent/JP2001521889A/en
Priority to EP98955026A priority patent/EP1027048A2/en
Priority to AU11926/99A priority patent/AU758566B2/en
Priority to CA002308639A priority patent/CA2308639A1/en
Priority to BR9813164-8A priority patent/BR9813164A/en
Publication of WO1999022720A2 publication Critical patent/WO1999022720A2/en
Publication of WO1999022720A3 publication Critical patent/WO1999022720A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

This invention relates to the use of selective cyclooxygenase-2 inhibitors or derivatives thereof in preventing and treating preterm labor. In particular, the invention describes the method of maintaining the fetal ductus arteriosus during prevention and treatment preterm labor in a subject, said method comprising treating the subject with a therapeutically-effective amount of a compound of Formula (I).
PCT/US1998/022246 1997-10-31 1998-10-27 Selective cyclooxygenase-2 inhibitors against premature labor Ceased WO1999022720A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2000518654A JP2001521889A (en) 1997-10-31 1998-10-27 Use of cyclooxygenase-2 inhibitors to maintain fetal arterial tract during treatment and prevention of preterm labor
EP98955026A EP1027048A2 (en) 1997-10-31 1998-10-27 Selective cyclooxygenase-2 inhibitors against premature labor
AU11926/99A AU758566B2 (en) 1997-10-31 1998-10-27 Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor
CA002308639A CA2308639A1 (en) 1997-10-31 1998-10-27 Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor
BR9813164-8A BR9813164A (en) 1997-10-31 1998-10-27 Method of using cyclooxygenase-2 inhibitors to maintain the fetal arterial duct during treatment and prevent premature labor pains

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6388997P 1997-10-31 1997-10-31
US60/063,889 1997-10-31

Publications (2)

Publication Number Publication Date
WO1999022720A2 WO1999022720A2 (en) 1999-05-14
WO1999022720A3 true WO1999022720A3 (en) 1999-08-26

Family

ID=22052179

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/022246 Ceased WO1999022720A2 (en) 1997-10-31 1998-10-27 Selective cyclooxygenase-2 inhibitors against premature labor

Country Status (9)

Country Link
EP (1) EP1027048A2 (en)
JP (1) JP2001521889A (en)
AR (1) AR014000A1 (en)
AU (1) AU758566B2 (en)
BR (1) BR9813164A (en)
CA (1) CA2308639A1 (en)
TW (2) TW577739B (en)
WO (1) WO1999022720A2 (en)
ZA (1) ZA989876B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001274858A1 (en) * 2000-06-08 2001-12-17 Board Of Regents, The University Of Texas System Heterocycle derivatives and methods of use for treating anthrax infection
PL1745791T3 (en) 2003-05-07 2013-11-29 Osteologix As Treating cartilage/bone conditions with water-soluble strontium salts

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521207A (en) * 1993-11-30 1996-05-28 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamide for the treatment of inflammation
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6718494A (en) * 1993-05-13 1994-12-12 Merck Frosst Canada Inc. 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
EP0889724A1 (en) * 1996-02-27 1999-01-13 Rpms Technology Limited Cox-2 selective inhibitors for managing labour and uterine contractions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521207A (en) * 1993-11-30 1996-05-28 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamide for the treatment of inflammation
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BOTTING: "COX-2 : selective inhibitors in clinical trials", DRUG NEWS AND PERSPECTIVES, vol. 9, no. 2, 1996, pages 123 - 128, XP002104738 *
DATABASE EMBASE ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; XP002104739 *
KATORI ET AL.: "Multiple roles of inducible cyclooxygenase-2 and its selective inhibitors", FOLIA PHARMACOLOGICA JAPONICA, vol. 109, no. 6, 1 June 1997 (1997-06-01), pages 247 - 258 *
SMITH: "The pharmacology of the ductus arteriosus", PHARMACOL. REVIEWS, vol. 50, no. 1, 1 March 1998 (1998-03-01), pages 35 - 50, XP002104737 *
VANE ET AL.: "Cyclooxygenases 1 and 2", ANN. REV. PHARMOCOL. TOXICOL., vol. 38, 1 January 1998 (1998-01-01), pages 97 - 120, XP002074177 *
VANE ET AL.: "Mechanism of action of antiinflammatory drugs", INT. J. TISSUE REACT., vol. 20, no. 1, January 1998 (1998-01-01), pages 3 - 15, XP002104736 *
VANE ET AL.: "Mechanism of action of aspirin-like drugs", SEMIN. ARTHRITIS RHEUM., vol. 26, no. 6sup1, June 1997 (1997-06-01), pages 2 - 10, XP002104735 *

Also Published As

Publication number Publication date
JP2001521889A (en) 2001-11-13
EP1027048A2 (en) 2000-08-16
WO1999022720A2 (en) 1999-05-14
ZA989876B (en) 1999-10-29
AU758566B2 (en) 2003-03-27
BR9813164A (en) 2000-08-22
TW200404535A (en) 2004-04-01
AU1192699A (en) 1999-05-24
TW577739B (en) 2004-03-01
CA2308639A1 (en) 1999-05-14
AR014000A1 (en) 2001-01-31

Similar Documents

Publication Publication Date Title
WO1999004752A3 (en) Methods for treating skin pigmentation
CA2258606A1 (en) Crystal form ii of clarithromycin
WO2004019791A3 (en) Device for closure of a vascular defect and method for treating the same
CA2201123A1 (en) Method of hair removal
EP0935963A3 (en) The use of MMP-13 selective inhibitors for the treatment of osteoarthritis and other matrix metalloproteinase-mediated disorders
WO2002098444A3 (en) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
AU2001262723A1 (en) 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
DK1066056T4 (en) Iron dextran compound for use as a component of a therapeutic agent for the prevention or treatment of iron deficiency, method of preparing the iron dextran compound and use of this compound for the manufacture of an ...
EP0690044A3 (en) Process for producing amidoether carboxylic acid or salt thereof, and surface active agent mixture containing the same
WO2002034201A3 (en) Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy
WO1998036730A3 (en) Compositions for treating acne rosacea
WO2002028434A3 (en) Use of a ppar delta activator for treating inflammatory conditions
MXPA03004303A (en) Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain.
EP0943311A3 (en) Method of inhibiting hair growth
MXPA00007394A (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases.
WO1999022720A3 (en) Selective cyclooxygenase-2 inhibitors against premature labor
WO2001041709A3 (en) Methods for treating cell death diseases and inflammation
AU4259299A (en) New sequences of tt viruses for use in diagnosis, prevention and treatment of ttv infections
WO2005042718A3 (en) Compositions and methods for treating, preventing, reversing and inhibiting pain
AU6502194A (en) Oestriol-containing hormonal agent for the prophylaxis and treatment of arterial conditions in humans, method of preparing it and its use
CA2149209A1 (en) Use of Topically Applied Factor XIII for Inhibiting Hemorrhage
WO1999066780A3 (en) Cinoxacin lanthanide chelates and their use as biomolecular probes
AU5868699A (en) Novel therapeutic use of compounds with beta-3-agonist activity
ZA982808B (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
WO2002005796A3 (en) Use of a spla2 inhibitor for the treatment of sepsis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 11926/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2308639

Country of ref document: CA

Ref document number: 2308639

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 518654

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998955026

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/A/2000/004204

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1998955026

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 11926/99

Country of ref document: AU